Imantinib base
Imatinib
CAS: 152459-95-5
Molecular Formula: C29H31N7O
Imantinib base - Names and Identifiers
| Name | Imatinib |
| Synonyms | IMA-3 Veenat Imatinib AKOS 91378 IMATINIB-D3 IMatinib-D4 Imatinib Base Imantinib base IMatinib(STI571) Imatinib free base 4-(4-Methyl-piperazin-1-ylMethyl)-N-[4-Methyl-3-(4-pyridin-3-yl-pyriMidin-2-ylaM 4-(4-METHYL-PIPERAZIN-1-YLMETHYL)-N-[4-METHYL-3-(4-PYRIDIN-3-YL-PYRIMIDIN-2-YLAMINO)-PHENYL]-BENZAMIDE 4-[(4-methylpiperazin-1-yl)methyl]-N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)benzamide Imatinib (4-[(4-Methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide |
| CAS | 152459-95-5 |
| EINECS | 604-855-6 |
| InChI | InChI=1/C29H31N7O.CH4O3S/c1-21-5-10-25(18-27(21)34-29-31-13-11-26(33-29)24-4-3-12-30-19-24)32-28(37)23-8-6-22(7-9-23)20-36-16-14-35(2)15-17-36;1-5(2,3)4/h3-13,18-19H,14-17,20H2,1-2H3,(H,32,37)(H,31,33,34);1H3,(H,2,3,4) |
Imantinib base - Physico-chemical Properties
| Molecular Formula | C29H31N7O |
| Molar Mass | 493.6 |
| Density | 1?+-.0.06 g/cm3(Predicted) |
| Melting Point | 208-210°C (dec.) |
| Boling Point | 754.9°C at 760 mmHg |
| Flash Point | 410.3°C |
| Solubility | Soluble in DMSO |
| Vapor Presure | 6.03E-24mmHg at 25°C |
| Appearance | yellowish to white crystalline powder |
| Color | White to Pale Beige |
| Merck | 14,4902 |
| pKa | pKa1 8.07; pKa2 3.73; pKa3 2.56; pKa4 1.52(at 25℃) |
| Storage Condition | Keep in dark place,Sealed in dry,Store in freezer, under -20°C |
| MDL | MFCD05662257 |
| In vitro study | In vitro inhibition of a panel of tyrosine and serine/threonine protein kinases demonstrated that Imatinib effectively inhibited v-Abl tyrosine kinases and PDGFR with IC50 of 0.6 and 0.1 μm, respectively. Imatinib inhibited SLF-dependent activation of wild-type c-kit kinase activity with an IC50 of approximately 0.1 μm, similar to the concentration required to inhibit PDGFR. Imatinib inhibited the growth of human bronchial carcinoid cell NCI-H727 and pancreatic carcinoid cell BON-1 with IC50 of 32.4 and 32.8 μm, respectively. Recent studies have shown that Imatinib acts on chronic myeloid leukemia and has the potential to restore its anti-leukemia effect by down-regulating the hERG1 K() channel, which is highly expressed in leukemia cells, and easy to cause leukemia. |
| In vivo study | Imatinib had different antitumor effects on three xenografts derived from fresh human small cell lung cancer, inhibiting SCLC6, SCLC61 and SCLC108 tumor growth by 80%, 40% and 78%, respectively, there was no significant inhibitory effect on the growth of sclc74. Imatinib treatment of high-fat-fed ApoE(-/-) mice significantly reduced high-fat-induced lipid staining zones, fed at doses of 10,20 and 40 mg/kg, compared with the control group without high fat diet treatment, the lipid staining area was reduced by 30%, 27% and 35%, respectively, and the carotid lipid accumulation was inhibited. |
Imantinib base - Risk and Safety
| Safety Description | 24/25 - Avoid contact with skin and eyes. |
| RTECS | CV5585673 |
| HS Code | 29339900 |
Imantinib base - Nature
Open Data Verified Data
melting point 211-213 °c.
Last Update：2024-01-02 23:10:35
Imantinib base - Preparation Method
Open Data Verified Data
N-(5-amino-2-methylphenyl)-4-(3-pyridyl)-2-pyrimidinamine and 4-(4-methylpiperazinomethyl) the benzoyl chloride was dissolved in pyridine and stirred at room temperature under nitrogen. Concentrate under reduced pressure, add water, cool, filter, dry filter cake under vacuum, add dichloromethane-methanol, and filter again. The product imatinib was obtained.
Last Update：2022-01-01 09:09:20
Imantinib base - Use
Open Data Verified Data
tyrosine kinase inhibitors. It is used in the blast crisis phase, accelerated phase and chronic phase of chronic myelogenous leukemia (CML) that is refractory to interferon alpha therapy, and gastrointestinal interstitial tumor (GIST). Imatinib Mesylate in vitro and in vivo can inhibit Bcr Abl tyrosine kinase at the cellular level, can selectively inhibit Bcr-Abl positive cell line cells, proliferation and induction of apoptosis of fresh cells from patients with Ph chromosome-positive chronic myelogenous leukemia and acute lymphoblastic leukemia. In addition, imatinib mesylate can also inhibit platelet-derived growth factor (PDGF) receptor, stem cell factor (SCF),c-Kit receptor tyrosine, thereby inhibiting cell behavior mediated by PDGF and stem cell factor.
Last Update：2022-01-01 09:09:21
Supplier List
Spot supply
Product Name: Imatinib Visit Supplier Webpage Request for quotationCAS: 152459-95-5
Tel: 0714-3999186
Email: 2853786052@qq.com
Mobile: 86+15671228036
QQ: 2853786052
Wechat: 15671228036
Multiple SpecificationsSpot supply
Product Name: Imatinib Visit Supplier Webpage Request for quotationCAS: 152459-95-5
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
Spot supply
Product Name: Imatinib Visit Supplier Webpage Request for quotationCAS: 152459-95-5
Tel: 0714-3999186
Email: 2853786052@qq.com
Mobile: 86+15671228036
QQ: 2853786052
Wechat: 15671228036
Multiple SpecificationsSpot supply
Product Name: Imatinib Visit Supplier Webpage Request for quotationCAS: 152459-95-5
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
View History